5 results about "Etanercept" patented technology

To provide an etanercept pharmaceutical composition, a method for producing the same, and a method for treating a patient having rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or psoriasis.SOLUTION: A pharmaceutical composition comprising 75mM to 150mM NaCl, 5mM to 100mM arginine, 0.5% to 2% (w / v) sucrose, and 40mg to 100mg / mL etanercept, wherein the composition comprises 2. less than 0mM total additional buffer, and wherein the pH of the composition is between 6.1 and 6.5.SELECTED DRAWING: Figure 1

This invention discloses a multi-drug composition for the treatment of ankylosing spondylitis. For the first time, this invention addresses the etiology of streptococcus-related diseases by proposing a synergistic treatment strategy combining a classic tumor necrosis factor antagonist (such as etanercept) with a narrow-spectrum antibiotic (benzathine penicillin). This approach breaks through the traditional treatment strategy that targets only the inflammatory pathway, providing a novel entry point for AS treatment.

Methods for mixing fluids including etanercept include providing a tank having an impeller with a 10 inch blade diameter disposed therein, filling a tank with a liquid composition comprising etanercept and one or more buffers to a level within the tank to cover the impeller, and operating the impeller to mix the liquid composition to a homogeneous state while maintaining a maximum shear stress imparted on the mixture of fluids at 125,000 s−1 or below.

The present invention provides improved Etanercept variants which comprise one (A105E), preferably two (A105E / L106F), amino acid substitutions regarding the Etanercept original amino acid sequence of SEQ ID NO: 3. These variants inhibit TNF activity but fail to neutralize human LTα (hLTα). Thus, they are proposed herein as a great alternative to be used in the clinic for the treatment of autoimmune or inflammatory diseases in which an exacerbated TNF activity is involved, since they prevent the side effects associated to the use of the original Etanercept molecule while retaining the TNF blocking activity.

The present disclosure relates to etanercept variants and related processes, wherein the variants are specific truncated variants of etanercept. The present application also provides pharmaceutical formulations comprising the variants described above. The invention further provides a method for reducing the variant, the content of truncated variant fragments can be effectively optimized through the method, and the method is simple in process and easy to operate.